Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma (Q40702544)

22 September 2017

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma (English)

1 reference

22 September 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Mohammed Milhem

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

David Minor

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Omid Hamid

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Ai Li

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Lisa Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Michael Chastain

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Kevin S Gorski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Abraham Anderson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Jeffrey Chou

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Howard L Kaufman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Robert H I Andtbacka

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

13 June 2016

1 reference

Journal of Clinical Oncology

22 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

2619-2626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo

8 June 2020

cites work

1 reference

12 December 2020

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

1 reference

12 December 2020

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

12 December 2020

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

12 December 2020

Hallmarks of Cancer: The Next Generation

1 reference

12 December 2020

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

1 reference

12 December 2020

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

1 reference

12 December 2020

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 December 2020

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

12 December 2020

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

12 December 2020

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

1 reference

12 December 2020

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma

1 reference

12 December 2020

Immunomodulation: the role of hematopoietic cytokines

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

1 reference

12 December 2020

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

12 December 2020

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 December 2020

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer

1 reference

12 December 2020

PD-1 as a potential target in cancer therapy

1 reference

12 December 2020

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

1 reference

12 December 2020

GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances.

1 reference

12 December 2020

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

12 December 2020

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Ipilimumab: controversies in its development, utility and autoimmune adverse events

1 reference

12 December 2020

CTLA-4 blockade: autoimmunity as treatment

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2016.67.1529

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27298410%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference